What is Lifesci Capital’s Estimate for AVDL Q2 Earnings?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Investment analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a report issued on Monday, March 3rd. Lifesci Capital analyst M. Belghiti expects that the company will post earnings of $0.02 per share for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share.

A number of other research analysts also recently weighed in on AVDL. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Avadel Pharmaceuticals in a research note on Tuesday. Piper Sandler dropped their price target on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. UBS Group dropped their price target on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of Avadel Pharmaceuticals in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They set a “buy” rating and a $12.00 price target on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $19.88.

Avadel Pharmaceuticals Price Performance

Shares of NASDAQ:AVDL opened at $7.87 on Thursday. The company has a market capitalization of $758.37 million, a price-to-earnings ratio of -9.96 and a beta of 1.28. The business’s 50-day moving average is $8.72 and its 200-day moving average is $11.48. Avadel Pharmaceuticals has a 1 year low of $7.39 and a 1 year high of $19.09.

Insiders Place Their Bets

In related news, Director Linda Palczuk acquired 3,000 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was purchased at an average cost of $10.19 per share, with a total value of $30,570.00. Following the acquisition, the director now owns 66,400 shares of the company’s stock, valued at approximately $676,616. This trade represents a 4.73 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas S. Mchugh acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were bought at an average cost of $10.49 per share, with a total value of $52,450.00. Following the completion of the acquisition, the chief financial officer now directly owns 85,500 shares in the company, valued at approximately $896,895. This represents a 6.21 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 55,579 shares of company stock valued at $526,363. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Institutional investors have recently modified their holdings of the business. FMR LLC bought a new position in shares of Avadel Pharmaceuticals in the third quarter valued at approximately $31,000. Advisors Asset Management Inc. grew its holdings in shares of Avadel Pharmaceuticals by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock valued at $104,000 after acquiring an additional 2,846 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Avadel Pharmaceuticals in the fourth quarter valued at approximately $113,000. Kazazian Asset Management LLC bought a new position in shares of Avadel Pharmaceuticals in the fourth quarter valued at approximately $126,000. Finally, Sanctuary Advisors LLC bought a new position in shares of Avadel Pharmaceuticals in the fourth quarter valued at approximately $140,000. 69.19% of the stock is owned by institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.